LEADER 05063nam 2201297z- 450 001 9910367754703321 005 20231214133529.0 010 $a3-03921-190-0 035 $a(CKB)4100000010106170 035 $a(oapen)https://directory.doabooks.org/handle/20.500.12854/61900 035 $a(EXLCZ)994100000010106170 100 $a20202102d2019 |y 0 101 0 $aeng 135 $aurmn|---annan 181 $ctxt$2rdacontent 182 $cc$2rdamedia 183 $acr$2rdacarrier 200 10$aVenom and Toxin as Targeted Therapy 210 $cMDPI - Multidisciplinary Digital Publishing Institute$d2019 215 $a1 electronic resource (180 p.) 311 $a3-03921-189-7 330 $aTargeted therapy has developed significantly in the last one and half decades, prescribing specific medications for treatment of particular diseases, such as cancer, diabetes, and heart disease. One of the most exciting recent developments in targeted therapies was the isolation of disease-specific molecules from natural resources, such as animal venoms and plant metabolites/toxins, for use as templates for new drug motif designs. In addition, the study of venom proteins/peptides and toxins naturally targeted mammalian receptors and demonstrated high specificity and selectivity towards defined ion channels of cell membranes. Research has also focsed intensely on receptors. The focus of this Special Issue of Toxins addressed the most recent advances using animal venoms, such as frog secretions, bee/ant venoms and plant/fungi toxins, as medicinal therapy. Recent advances in venom/toxin/immunotoxins for targeted cancer therapy and immunotherapy, along with using novel disease-specific venom-based protein/peptide/toxin and currently available FDA-approved drugs for combinationtreatments will be discussed. Finally, we included an overview of select promising toad/snake venom-based peptides/toxins potentially able to address the forthcoming challenges in this field. Both research and review articles proposing novelties or overviews, respectively, were published in this Special Issue after rigorous evaluation and revision by expert peer reviewers. 610 $acane toad 610 $aB cell non-Hodgkin lymphoma 610 $aMalaysian cobras 610 $acomplement system 610 $adecay accelerating factor 610 $aneuroblastoma 610 $aatopic dermatitis 610 $acomplement dependent cytotoxicity 610 $aantioxidant enzymes 610 $abacterial adhesion 610 $acancer therapy 610 $aN. kaouthia 610 $aanuran skin secretion 610 $afrog 610 $aApis mellifera syriaca 610 $asolid phase extraction 610 $abee venom phospholipase A2 (bvPLA2) 610 $adisintegrin 610 $atoad toxins 610 $aimmunotoxins 610 $aribosome-inactivating proteins 610 $aantimicrobial peptide (AMP) 610 $adrug design 610 $aMoxetumomab pasudotox 610 $asnake venom 610 $aantiviral activity 610 $ain vitro effects 610 $abombesin-related peptide 610 $aoxidative stress biomarkers 610 $ahalf-life 610 $ablood vessel formation 610 $atarget therapy 610 $a2 610 $aMYCN 610 $aindolealkylamines 610 $aHuachansu 610 $amembrane attack complex 610 $abouganin 610 $abee venom 610 $aSEM 610 $aanticancer activity 610 $aantimicrobial peptide 610 $ahouse dust mite extract (DFE) 610 $amannose receptor 610 $aO. hannah 610 $abicarinalin 610 $agastric cells 610 $amelittin 610 $aLC-ESI-MS 610 $adermaseptin 610 $asmooth muscle 610 $aapoptosis 610 $aanticancer 610 $aN. sumatrana 610 $aHelicobacter pylori 610 $ainflammation 610 $aimmunotherapy 610 $aatopic dermatitis (AD) 610 $aimmunotoxin 610 $amantle cell lymphoma 610 $aclearance 610 $amass spectrometry 610 $aBougainvillea 610 $arRNA N-glycosylase activity 610 $afungal toxin 610 $askin inflammation 610 $atargeted therapy 610 $a4-dinitrochlorobenzene (DNCB) 610 $aBee venom 610 $aVEGF 610 $aChansu 610 $abufadienolides 610 $aobsessive-compulsive disorder (OCD) 610 $aBLF1 610 $aantimicrobial activity 610 $aorellanine 610 $aVB6-845 610 $aacute lymphoblastic leukemia 610 $aribosome-inactivating protein 610 $aCD206 610 $amolecular cloning 610 $acancer 610 $aCD22 610 $aeIF4A 700 $aKwok$b Hang Fai (Henry)$4auth$01320455 906 $aBOOK 912 $a9910367754703321 996 $aVenom and Toxin as Targeted Therapy$93034329 997 $aUNINA